Success Metrics

Clinical Success Rate
89.3%

Based on 192 completed trials

Completion Rate
89%(192/215)
Active Trials
12(5%)
Results Posted
64%(123 trials)
Terminated
23(9%)

Phase Distribution

Ph not_applicable
13
5%
Ph phase_3
55
21%
Ph phase_4
74
29%
Ph phase_1
26
10%
Ph early_phase_1
3
1%
Ph phase_2
50
19%

Phase Distribution

29

Early Stage

50

Mid Stage

129

Late Stage

Phase Distribution221 total trials
Early Phase 1First-in-human
3(1.4%)
Phase 1Safety & dosage
26(11.8%)
Phase 2Efficacy & side effects
50(22.6%)
Phase 3Large-scale testing
55(24.9%)
Phase 4Post-market surveillance
74(33.5%)
N/ANon-phased studies
13(5.9%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

86.1%

192 of 223 finished

Non-Completion Rate

13.9%

31 ended early

Currently Active

12

trials recruiting

Total Trials

258

all time

Status Distribution
Active(15)
Completed(192)
Terminated(31)
Other(20)

Detailed Status

Completed192
Terminated23
unknown20
Withdrawn8
Recruiting8
Active, not recruiting4

Development Timeline

Analytics

Development Status

Total Trials
258
Active
12
Success Rate
89.3%
Most Advanced
Phase 4

Trials by Phase

Early Phase 13 (1.4%)
Phase 126 (11.8%)
Phase 250 (22.6%)
Phase 355 (24.9%)
Phase 474 (33.5%)
N/A13 (5.9%)

Trials by Status

terminated239%
withdrawn83%
unknown208%
active_not_recruiting42%
not_yet_recruiting31%
completed19274%
recruiting83%

Recent Activity

Clinical Trials (258)

Showing 20 of 258 trialsScroll for more
NCT03997786Phase 2

A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis

Active Not Recruiting
NCT06011889Phase 2

Study of the Efficacy and Safety of Etanercept Treatment in Patients With SAPHO Syndrome

Recruiting
NCT06016517

Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis

Not Yet Recruiting
NCT03451851Phase 3

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants

Active Not Recruiting
NCT02840175Phase 3

Treatment Tapering in JIA With Inactive Disease

Completed
NCT04066348Phase 2

TNF-α Treatment of Blast-Induced Tinnitus

Recruiting
NCT07352566Phase 4

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

Not Yet Recruiting
NCT03792841Phase 1

Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC

Terminated
NCT07138898Phase 2

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

Not Yet Recruiting
NCT03414502Phase 3

Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response

Recruiting
NCT06707194Phase 4

Effect and Safety of Benzathine Penicillin Combined With Etanercept on Spondyloarthritis

Recruiting
NCT02713997Phase 4

Anti-inflammatory Therapy to Improve Outcomes After TPIAT

Completed
NCT04973566Phase 1

A Study of Nipocalimab With Co-administration of Etanercept or Hydroxychloroquine in Healthy Participants

Completed
NCT04254627Phase 1

TNF and Glucocorticoid Antagonist for GWI Associated Multi-symptom Disease Homeostasis Reset

Active Not Recruiting
NCT03976245Phase 4

Advanced Therapeutics in Rheumatoid Arthritis (RA)

Recruiting
NCT01706692

Swiss Dermatology Network of Targeted Therapies (SDNTT)

Recruiting
NCT02308163Phase 3

A Study to Evaluate Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to DMARDs

Completed
NCT03728478Phase 3

STep-up and Step-down Therapeutic Strategies in Childhood ARthritiS

Recruiting
NCT04485325Phase 4

Capability of Tofacitinib or Etanercept to Accelerate Tapering of NSAID and Treat-to-target Guided De-escalation of Corticosteroids in RA Patients

Completed
NCT04725422

CHronic Nonbacterial Osteomyelitis International Registry

Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
258